| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC3755 |
| Trial ID | NCT06253520 |
| Disease | Colorectal Cancer | Breast Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Ovarian Cancer | Genitourinary Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KRAS TCR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer |
| Year | 2024 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10001662|001662-C |
| Cohort 1 | |||||||||||
|
|||||||||||